Nov 13 (Reuters) - Vertex Pharmaceuticals Inc said on Wednesday cystic fibrosis patients in Wales would get access to the company’s life-extending drugs following an agreement with the state-funded health service.
The U.S. drugmaker has already reached similar agreements with the National Health Service in Northern Ireland, England and Scotland.
More than 10,000 people in Britain have cystic fibrosis, a debilitating, life-shortening inherited condition.
The agreement with Wales will allow about 270 eligible patients to be treated with the company’s medicines Orkambi, Symkevi and Kalydeco. (Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila)
Our Standards: The Thomson Reuters Trust Principles.